MedPath

DS BIOPHARMA LIMITED

🇮🇪Ireland
Ownership
-
Employees
-
Market Cap
-
Website

Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

Phase 2
Terminated
Conditions
Atopic Dermatitis
Interventions
Drug: Placebo
First Posted Date
2019-01-25
Last Posted Date
2022-11-28
Lead Sponsor
DS Biopharma
Target Recruit Count
219
Registration Number
NCT03817190
Locations
🇺🇸

DS Investigational Site 527, Doral, Florida, United States

🇺🇸

DS Investigational Site 521, Medford, Oregon, United States

🇦🇹

DS Investigational Site 101, Graz, Austria

and more 47 locations

Efficacy and Steroid Sparing Potential Study of DGLA Cream in Early Childhood Patients With Moderate to Severe Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
First Posted Date
2018-09-19
Last Posted Date
2019-02-08
Lead Sponsor
DS Biopharma
Target Recruit Count
5
Registration Number
NCT03676933
Locations
🇮🇪

DS Biopharma Investigational Site, Dublin, Ireland

Efficacy and Steroid Sparing Potential Study of DGLA Cream in Patients With Moderate to Severe Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: Vehicle
First Posted Date
2018-09-18
Last Posted Date
2018-09-18
Lead Sponsor
DS Biopharma
Target Recruit Count
42
Registration Number
NCT03676036
Locations
🇩🇪

DS Biopharma Investigational Site, Lubeck, Germany

Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Other: Vehicle cream
First Posted Date
2016-10-06
Last Posted Date
2022-11-22
Lead Sponsor
DS Biopharma
Target Recruit Count
327
Registration Number
NCT02925793
Locations
🇿🇦

DS Biopharma Site, Cape Town, South Africa

Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: Placebo
First Posted Date
2016-08-12
Last Posted Date
2022-10-10
Lead Sponsor
DS Biopharma
Target Recruit Count
321
Registration Number
NCT02864498
Locations
🇿🇦

DS Biopharma Site, Cape Town, South Africa

Safety and Efficacy Study of Orally Administered DS102 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2016-02-04
Last Posted Date
2016-02-04
Lead Sponsor
DS Biopharma
Target Recruit Count
57
Registration Number
NCT02673593
Locations
🇮🇪

DS Biopharma Investigational Site, Belfast, Ireland

© Copyright 2025. All Rights Reserved by MedPath